Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bolt Biotherapeutics's Enterprise Value is $7.64 Mil.
Bolt Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-30.12 Mil. Therefore, Bolt Biotherapeutics's EV-to-EBIT ratio for today is -0.25.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Bolt Biotherapeutics's Enterprise Value is $7.64 Mil.
Bolt Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-29.02 Mil. Therefore, Bolt Biotherapeutics's EV-to-EBITDA ratio for today is -0.26.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Bolt Biotherapeutics (NAS:BOLT) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Bolt Biotherapeutics's current Enterprise Value is $7.64 Mil.
Bolt Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-30.12 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Bolt Biotherapeutics's current Enterprise Value is $7.64 Mil.
Bolt Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.02 Mil.
Bolt Biotherapeutics's current Enterprise Value is $7.64 Mil.
Bolt Biotherapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.50 Mil.
Bolt Biotherapeutics's current Enterprise Value is $7.64 Mil.
Bolt Biotherapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.51 Mil.
Bolt Biotherapeutics's current Enterprise Value is $7.64 Mil.
Bolt Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bolt Biotherapeutics Enterprise Value Related Terms
Bolt Biotherapeutics Enterprise Value Historical Data
* Premium members only.
The historical data trend for Bolt Biotherapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOLT vs BCDA, NCNA, PBM: Enterprise Value Comparison
For the Biotechnology subindustry, Bolt Biotherapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bolt Biotherapeutics Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Bolt Biotherapeutics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Bolt Biotherapeutics's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bolt Biotherapeutics (BOLT) has a Enterprise Value of $7.64 Mil as of Jun. 26, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Bolt Biotherapeutics and its competitors.
Is Bolt Biotherapeutics' Enterprise Value too high?
Bolt Biotherapeutics' current Enterprise Value is $7.64 Mil. Overall, Bolt Biotherapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bolt Biotherapeutics' Enterprise Value compare to BCDA and NCNA?
Bolt Biotherapeutics' Enterprise Value of $7.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Bolt Biotherapeutics and its competitors. Bolt Biotherapeutics's current Enterprise Value is $7.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bolt Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bolt Biotherapeutics (BOLT) is currently considered Possible Value Trap. The stock's GF Value™ is $9.03, compared to a current price of $4.28 — trading 52.6% below its estimated fair value. The current Enterprise Value is $7.64 Mil. Bolt Biotherapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Bolt Biotherapeutics (BOLT), the current Enterprise Value is $7.64 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bolt Biotherapeutics (BOLT) Overvalued in 2026?
Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued.
The current stock price of $4.28 is trading 52.6% below its estimated GF Value™ of $9.03.
GuruFocus considers Bolt Biotherapeutics to be Possible Value Trap.
Key valuation signals for BOLT:
Enterprise Value: $7.64 Mil
GF Value™: $9.03 vs. price of $4.28 (52.6% below fair value)
No single metric tells the full story. See the BOLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
55GF Score
Get the complete analysis for BOLT
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOLT has been successfully added to your 
